Print

Lupin Ltd. (LUPN.BO) Eyes Acquisitions of Up to $500 Million in U.S.  
8/1/2012 8:26:35 AM

Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs. The U.S. is Lupin's primary growth market, accounting for 35% of its sales. The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.
//-->